Developer docs
API playgroundTry for free, no card

Search company profiles

DCVC Bio

Full company profile

uuid00000ng

Namestring
DCVC Bio
Legal namestring
DCVC Management Co, LLC
Websiteurl
dcvc.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

DCVC Bio is the life-sciences franchise of DCVC (Data Collective), a deep-tech venture capital firm, established in 2018 and co-founded by Managing Partners Dr. John Hamer, Dr. Kiersten Stead, Matthew Ocko, and Zachary Bogue. The firm invests in early-stage life-sciences companies applying AI, computational biology, and engineering biology across three verticals: human health, agriculture, and synthetic biology. Its underlying investment approach combines large-data models and scientific-domain expertise in genetics, chemistry, molecular biology, industrial fermentation, and AI to evaluate networks of genes and proteins and identify breakthrough opportunities in medicines, materials, and farming methods.

The firm's offering is a fund-plus-portfolio platform rather than a discrete software product. It manages three dedicated DCVC Bio funds — with DCVC Bio III closing at $400 million in September 2024 — and backs a portfolio that includes AbCellera (antibody discovery, Nasdaq: ABCL), Creyon Bio (ML-designed oligonucleotide therapeutics, partnered with Eli Lilly), Umoja Biopharma (in vivo CAR-T for cancer), Relation Therapeutics (graph machine-learning drug discovery, partnered with Novartis, GSK, and Deerfield), Kanvas Biosciences (microbiome therapeutics), Nilo Therapeutics (neuro-immunology), Newleos Therapeutics (CNS drugs), Latus Bio (AAV gene therapy), Elo Life (molecular farming for food), MycoWorks (mycelium-based leather), Sabanto (autonomous agriculture), and AgZen (AI-driven pesticide and fertilizer optimization). Revenue is generated through standard VC fund economics — management fees on committed capital and carried interest on fund returns — negotiated bilaterally with institutional limited partners and not publicly disclosed. Go-to-market combines proactive scientific-founder sourcing with content-led thought leadership, including the annual Deep Tech Opportunities Report and topical series covering TechBio, Computational Bio & Chem, and Next-Gen Agriculture.

Short descriptiontext

DCVC Bio is the life-sciences franchise of DCVC, a deep-tech venture capital firm investing early-stage across human health, agriculture, and synthetic biology. Founded in 2018, it manages three funds — its most recent at $400 million — and backs companies applying AI and computational biology to medicines, materials, and farming.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital funding, life sciences investing, deep tech investment, biotech venture capital, computational biology investment
Industry1 code
PRIMARYFSANAHAA
Strategic / Balance-Sheet CVC (On-balance-sheet investing)
NAICS code1 code
  • Other Investment Pools and Funds5259
Product category
Life Sciences Venture Capital
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture capital fund management
TypeManaged Services
Description

DCVC Bio manages dedicated life-sciences funds (three funds to date, with DCVC Bio III closing at $400 million) and earns revenue through standard VC fund economics — management fees on committed capital and carried interest on fund returns. DCVC franchise overall manages over $4 billion in assets across 13 funds.

dcvc.com
Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1DCVC Bio
Description

Deep tech life sciences franchise of DCVC investing in computational biology and life sciences across human health, agriculture, and synthetic biology.

dcvc.com
Core offering1 text field

DCVC Bio manages dedicated life sciences venture capital funds that invest early-stage capital in deep-tech companies applying AI, computational biology, and engineering biology to human health, agriculture, and synthetic biology. The franchise comprises three funds (most recent, DCVC Bio III, closed at $400 million on 30 September 2024) and earns revenue through standard VC fund economics — management fees on committed capital and carried interest on fund returns. Beyond capital, DCVC Bio provides portfolio companies with scientific and operational support drawn from its team of PhD scientists and experienced operators.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DCVC Bio is the life sciences franchise of deep tech venture capital firm DCVC, established in 2018 to invest in human health, agriculture, and synthetic biology using frontier technologies such as AI, computation, and engineering biology. Rather than a single software product, DCVC Bio's offering is a fund-plus-portfolio platform: it manages three dedicated DCVC Bio funds (with DCVC Bio III closing at $400 million in September 2024) and backs a portfolio of breakthrough life sciences companies. Highlighted portfolio companies include AbCellera (antibody discovery), Creyon Bio (oligonucleotide design), Umoja Biopharma (in vivo CAR-T for cancer), Elo Life (molecular farming for food), MycoWorks (mycelium leather), Sabanto (autonomous agriculture), Relation Therapeutics (graph machine learning for drug discovery), Kanvas Biosciences (microbiome therapeutics), Nilo Therapeutics (neuro-immunology), Newleos Therapeutics (CNS drugs), Latus Bio (AAV gene therapy), and AgZen (AI/computer-vision spray optimization). The investment team's expertise spans genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI, and they combine scientific acumen with decades of operational management experience.

Product and service1 record
1DCVC Bio Investment Funds
CategoryVenture capital fund vehicle
Description

DCVC Bio manages three dedicated life sciences venture capital funds that deploy early-stage capital into deep-tech companies applying AI, computational biology, and engineering biology to human health, agriculture, and synthetic biology; limited partners commit capital to the funds and receive exposure to the portfolio. The third fund (DCVC Bio III) closed at $400 million on 30 September 2024.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Deep-tech and science-focused venture firm with a life-sciences franchise investing in AI-driven biotech, neuro-immunology, and frontier biology. Direct peer: co-invested with DCVC Bio on Nilo Therapeutics and pursues a comparable 'scientists not MBAs' sourcing model.

TypeDirect peer
Description

Pioneer in early-stage, science-driven life-sciences venture capital with deep exposure to computational biology, gene therapy, and platform biotechs. Direct peer in thesis and stage of investment, with comparable institutional LP base.

TypeDirect peer
Description

Multi-stage deep-tech investor with a large life-sciences and biotech franchise spanning therapeutics, agriculture, and synthetic biology. Direct peer in cross-sector deep-tech thesis and ability to lead large early-stage rounds.

TypeDirect peer
Description

Institutional originator of biotech platforms and investor in deep science (e.g., Moderna origin). Direct peer in life-sciences venture, with comparable scope across human health and sustainability.

TypeBroad incumbent
Description

Generalist mega-VC with a dedicated bio/health fund investing in AI-driven drug discovery, therapeutics, and digital health. Comparable in AI-meets-life-sciences thesis but operates at much broader scale and across more verticals.

TypeDirect peer
Description

Life-sciences-only venture firm investing in early-stage biotech and platform therapeutics. Direct peer in fund mandate and co-invested with DCVC Bio on Nilo Therapeutics.

TypeDirect peer
Description

Operationally driven deep-tech venture firm investing across bio, logistics, and frontier technology. Comparable peer that co-invested with DCVC Bio on Latus Bio's Series A.

TypeBroad incumbent
Description

Deep-tech generalist VC backing frontier science and technology companies. Comparable in deep-tech orientation and overlapping portfolio interests, though less focused on life sciences than DCVC Bio.

TypeEmerging player
Description

Venture fund focused on health-tech and computational biology at the intersection of technology and medicine. Comparable thesis on AI-driven biology, though smaller and more recent than DCVC Bio.

TypeOthers
Description

Large pharma partners of DCVC Bio portfolio companies (e.g., Creyon Bio with Eli Lilly) and increasingly active corporate VCs in AI-bio. Not direct fund-level peers, but adjacent ecosystem participants whose deal flow and validation shape DCVC Bio's outcomes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment69 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DCVC Bio

Life Sciences Venture Capitaldcvc.com

DCVC Bio is the life-sciences franchise of DCVC, a deep-tech venture capital firm investing early-stage across human health, agriculture, and synthetic biology. Founded in 2018, it manages three funds — its most recent at $400 million — and backs companies applying AI and computational biology to medicines, materials, and farming.

What DCVC Bio does

DCVC Bio is the life-sciences franchise of DCVC (Data Collective), a deep-tech venture capital firm, established in 2018 and co-founded by Managing Partners Dr. John Hamer, Dr. Kiersten Stead, Matthew Ocko, and Zachary Bogue. The firm invests in early-stage life-sciences companies applying AI, computational biology, and engineering biology across three verticals: human health, agriculture, and synthetic biology. Its underlying investment approach combines large-data models and scientific-domain expertise in genetics, chemistry, molecular biology, industrial fermentation, and AI to evaluate networks of genes and proteins and identify breakthrough opportunities in medicines, materials, and farming methods.

The firm's offering is a fund-plus-portfolio platform rather than a discrete software product. It manages three dedicated DCVC Bio funds — with DCVC Bio III closing at $400 million in September 2024 — and backs a portfolio that includes AbCellera (antibody discovery, Nasdaq: ABCL), Creyon Bio (ML-designed oligonucleotide therapeutics, partnered with Eli Lilly), Umoja Biopharma (in vivo CAR-T for cancer), Relation Therapeutics (graph machine-learning drug discovery, partnered with Novartis, GSK, and Deerfield), Kanvas Biosciences (microbiome therapeutics), Nilo Therapeutics (neuro-immunology), Newleos Therapeutics (CNS drugs), Latus Bio (AAV gene therapy), Elo Life (molecular farming for food), MycoWorks (mycelium-based leather), Sabanto (autonomous agriculture), and AgZen (AI-driven pesticide and fertilizer optimization). Revenue is generated through standard VC fund economics — management fees on committed capital and carried interest on fund returns — negotiated bilaterally with institutional limited partners and not publicly disclosed. Go-to-market combines proactive scientific-founder sourcing with content-led thought leadership, including the annual Deep Tech Opportunities Report and topical series covering TechBio, Computational Bio & Chem, and Next-Gen Agriculture.

DCVC Bio firmographics

Firmographics
Name
DCVC Bio
Legal name
DCVC Management Co, LLC
Website
https://dcvc.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
DCVC Bio is the life-sciences franchise of DCVC, a deep-tech venture capital firm investing early-stage across human health, agriculture, and synthetic biology. Founded in 2018, it manages three funds — its most recent at $400 million — and backs companies applying AI and computational biology to medicines, materials, and farming.
Ownership category
akta.pro rank

DCVC Bio industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Other Investment Pools and Funds (5259)
akta.pro industry
PRIMARYFSANAHAA
Strategic / Balance-Sheet CVC (On-balance-sheet investing)

Keywords

  • Venture capital funding
  • Life sciences investing
  • Deep tech investment
  • Biotech venture capital
  • Computational biology investment

Where DCVC Bio is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Markets served

DCVC Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Venture capital fund management: DCVC Bio manages dedicated life-sciences funds (three funds to date, with DCVC Bio III closing at $400 million) and earns revenue through standard VC fund economics — management fees on committed capital and carried interest on fund returns. DCVC franchise overall manages over $4 billion in assets across 13 funds.

Go-to-market motion2 records

DCVC Bio product offering

Product offering

Core offering

DCVC Bio manages dedicated life sciences venture capital funds that invest early-stage capital in deep-tech companies applying AI, computational biology, and engineering biology to human health, agriculture, and synthetic biology. The franchise comprises three funds (most recent, DCVC Bio III, closed at $400 million on 30 September 2024) and earns revenue through standard VC fund economics — management fees on committed capital and carried interest on fund returns. Beyond capital, DCVC Bio provides portfolio companies with scientific and operational support drawn from its team of PhD scientists and experienced operators.

Product overview

DCVC Bio is the life sciences franchise of deep tech venture capital firm DCVC, established in 2018 to invest in human health, agriculture, and synthetic biology using frontier technologies such as AI, computation, and engineering biology. Rather than a single software product, DCVC Bio's offering is a fund-plus-portfolio platform: it manages three dedicated DCVC Bio funds (with DCVC Bio III closing at $400 million in September 2024) and backs a portfolio of breakthrough life sciences companies. Highlighted portfolio companies include AbCellera (antibody discovery), Creyon Bio (oligonucleotide design), Umoja Biopharma (in vivo CAR-T for cancer), Elo Life (molecular farming for food), MycoWorks (mycelium leather), Sabanto (autonomous agriculture), Relation Therapeutics (graph machine learning for drug discovery), Kanvas Biosciences (microbiome therapeutics), Nilo Therapeutics (neuro-immunology), Newleos Therapeutics (CNS drugs), Latus Bio (AAV gene therapy), and AgZen (AI/computer-vision spray optimization). The investment team's expertise spans genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI, and they combine scientific acumen with decades of operational management experience.

Differentiator

Problem solved

Functional benefit

Brands

  • DCVC Bio: Deep tech life sciences franchise of DCVC investing in computational biology and life sciences across human health, agriculture, and synthetic biology.

Products and services

  • DCVC Bio Investment Funds DCVC Bio manages three dedicated life sciences venture capital funds that deploy early-stage capital into deep-tech companies applying AI, computational biology, and engineering biology to human health, agriculture, and synthetic biology; limited partners commit capital to the funds and receive exposure to the portfolio. The third fund (DCVC Bio III) closed at $400 million on 30 September 2024.

Companies that use DCVC Bio

Customer profile

Ideal customer profiles2 records

DCVC Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

DCVC Bio partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

DCVC Bio competitors and assessment

Company assessment

Direct peers

  • Lux Capital: Deep-tech and science-focused venture firm with a life-sciences franchise investing in AI-driven biotech, neuro-immunology, and frontier biology. Direct peer: co-invested with DCVC Bio on Nilo Therapeutics and pursues a comparable 'scientists not MBAs' sourcing model.
  • ARCH Venture Partners: Pioneer in early-stage, science-driven life-sciences venture capital with deep exposure to computational biology, gene therapy, and platform biotechs. Direct peer in thesis and stage of investment, with comparable institutional LP base.
  • Khosla Ventures: Multi-stage deep-tech investor with a large life-sciences and biotech franchise spanning therapeutics, agriculture, and synthetic biology. Direct peer in cross-sector deep-tech thesis and ability to lead large early-stage rounds.
  • Flagship Pioneering: Institutional originator of biotech platforms and investor in deep science (e.g., Moderna origin). Direct peer in life-sciences venture, with comparable scope across human health and sustainability.
  • The Column Group: Life-sciences-only venture firm investing in early-stage biotech and platform therapeutics. Direct peer in fund mandate and co-invested with DCVC Bio on Nilo Therapeutics.
  • 8VC: Operationally driven deep-tech venture firm investing across bio, logistics, and frontier technology. Comparable peer that co-invested with DCVC Bio on Latus Bio's Series A.

Broad incumbents

  • Andreessen Horowitz (a16z Bio): Generalist mega-VC with a dedicated bio/health fund investing in AI-driven drug discovery, therapeutics, and digital health. Comparable in AI-meets-life-sciences thesis but operates at much broader scale and across more verticals.
  • Founders Fund: Deep-tech generalist VC backing frontier science and technology companies. Comparable in deep-tech orientation and overlapping portfolio interests, though less focused on life sciences than DCVC Bio.

Emerging players

  • Section32: Venture fund focused on health-tech and computational biology at the intersection of technology and medicine. Comparable thesis on AI-driven biology, though smaller and more recent than DCVC Bio.

Others

  • AstraZeneca / Eli Lilly (as strategic pharma LPs and partners): Large pharma partners of DCVC Bio portfolio companies (e.g., Creyon Bio with Eli Lilly) and increasingly active corporate VCs in AI-bio. Not direct fund-level peers, but adjacent ecosystem participants whose deal flow and validation shape DCVC Bio's outcomes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

DCVC Bio social profiles

Digital presence

DCVC Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DCVC Bio leadership team

Management profile

Number of profiles

Profiles13 records

DCVC Bio subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

DCVC Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DCVC Bio M&A and investment

M&A and investment

M&A

Investments69 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DCVC Bio

What does DCVC Bio do?

DCVC Bio manages dedicated life sciences venture capital funds that invest early-stage capital in deep-tech companies applying AI, computational biology, and engineering biology to human health, agriculture, and synthetic biology. The franchise comprises three funds (most recent, DCVC Bio III, closed at $400 million on 30 September 2024) and earns revenue through standard VC fund economics — management fees on committed capital and carried interest on fund returns. Beyond capital, DCVC Bio provides portfolio companies with scientific and operational support drawn from its team of PhD scientists and experienced operators.

Is DCVC Bio a public or private company?

DCVC Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DCVC Bio founded?

DCVC Bio was founded in 2018. It employs 11 to 50 people.

Where is DCVC Bio based?

DCVC Bio is headquartered in Palo Alto, United States, in the North America region.

How does DCVC Bio make money?

One revenue line is on record: venture capital fund management.

Who are DCVC Bio's main competitors?

Direct peers on record are Lux Capital, ARCH Venture Partners, Khosla Ventures, Flagship Pioneering, The Column Group and 8VC. Broad incumbents are Andreessen Horowitz (a16z Bio) and Founders Fund. Section32 is listed as an emerging player. AstraZeneca / Eli Lilly (as strategic pharma LPs and partners) is listed as an others.

Does DCVC Bio have an API?

No public API is recorded for DCVC Bio.

What industry is DCVC Bio in?

DCVC Bio's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAHAA, Strategic / Balance-Sheet CVC (On-balance-sheet investing). Its NAICS code is 5259.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsAlchemab Therapeutics Extends Series A Financing with USD34MAlchemab Therapeutics raised £25M (USD$34M) in a Series A extension from British Business Bank, bringing total Series A funding to £109M. The funds will support its clinical pipeline and expand its proprietary antibody dataset to over a billion sequences.MorningstarSyntax Bio Announces Expanded Series A and Leadership AppointmentsSyntax Bio announced an expanded Series A bringing total funding to over $25 million, with proceeds supporting its Cellgorithm platform and pancreatic beta cell therapy for type 1 diabetes. The company also appointed new executives and board members to strengthen leadership.FinSMEsLatus Bio Raises $43M in Series A FundingLatus Bio raised $43M in Series A extension funding led by 8VC, with participation from existing and new investors. The funds will support operations and initial clinical data from its Huntington's disease and CLN2 disease programs. The company previously raised $54M in 2024.BioPharma DiveWith $97M, Latus pursues a different kind of Huntington’s gene therapyBiotechnology startup Latus Bio closed a $97 million Series A round, including a $43 million extension to a previously raised $54 million, to fund development of two gene therapies targeting Huntington's disease and Batten disease. The funding was led by 8VC with participation from DCVC Bio, BioAdvance and five other firms. The company's LTS-201 therapy for Huntington's works by targeting the MSH3 gene to inhibit a hazardous genetic phenomenon where a three-nucleotide sequence errantly repeats and expands, differentiating it from approaches like UniQure's that aim to stop production of the huntingtin protein itself.Venture Capital Access OnlineLatus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger PopulationsLatus Bio closed a $97 million Series A financing led by 8VC to advance its gene therapy pipeline. Proceeds will fund operations through key milestones, including initial clinical data from LTS-201 for Huntington's disease and LTS-101 for CLN2 disease. LTS-201 is on track for IND submission in 3Q 2026.VentureburnLatus Bio Raises $97M to Expand Gene Therapy PipelineLatus Bio raised $97 million in Series A funding to expand its gene therapy pipeline, targeting Huntington's disease and CLN2 disease. The company's engineered AAV capsids enable deep brain delivery at lower doses, with an IND submission planned for Q3 2026 for Huntington's.TechStartupsTop Startup and Tech Funding News – May 4, 2025Multiple startups raised significant funding in May 2026, including Sierra's $950M Series E and True Anomaly's $600M Series D. The rounds target AI infrastructure, space defense, and healthcare, with investors like Tiger Global and GV leading.TechStartupsKresus partners with Canton Network to accelerate institutional blockchain adoptionKresus and Canton Network announced a collaboration to help enterprises deploy blockchain applications in production, addressing execution challenges. Kresus is working with Hanwha Investment & Securities on a tokenized digital asset platform for private market assets, expected to enable issuance and management of tokenized financial instruments.TechStartupsBret Taylor’s AI startup Sierra raises $950M at $15.8B valuation as demand for AI agents surgesSierra, an AI customer service agent startup founded by Bret Taylor, raised $950 million at a $15.8 billion valuation. The company crossed $150 million in annual recurring revenue in eight quarters. Taylor expects a market shakeout over the next couple of years.pharmaphorumSyneron raises $150m for macrocyclics, and other financingsSyneron Bio closed a $150 million Series B, four months after its $100 million first round, to advance its macrocyclic peptide programs into clinical trials. The funding follows a $75 million upfront payment from AstraZeneca, which also participated in the round. Other biotech financings were also reported.